These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24422519)

  • 1. Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
    Hu Q; Yin L; Hartmann RW
    J Med Chem; 2014 Jun; 57(12):5011-22. PubMed ID: 24422519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.
    Lucas S; Negri M; Heim R; Zimmer C; Hartmann RW
    J Med Chem; 2011 Apr; 54(7):2307-19. PubMed ID: 21384875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
    Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
    J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
    Roumen L; Peeters JW; Emmen JM; Beugels IP; Custers EM; de Gooyer M; Plate R; Pieterse K; Hilbers PA; Smits JF; Vekemans JA; Leysen D; Ottenheijm HC; Janssen HM; Hermans JJ
    J Med Chem; 2010 Feb; 53(4):1712-25. PubMed ID: 20121113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
    Müller-Vieira U; Angotti M; Hartmann RW
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors.
    LaSala D; Shibanaka Y; Jeng AY
    Anal Biochem; 2009 Nov; 394(1):56-61. PubMed ID: 19622340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
    Bureik M; Hübel K; Dragan CA; Scher J; Becker H; Lenz N; Bernhardt R
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):249-54. PubMed ID: 15134825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.
    Adams CM; Hu CW; Jeng AY; Karki R; Ksander G; Lasala D; Leung-Chu J; Liang G; Liu Q; Meredith E; Rao C; Rigel DF; Shi J; Smith S; Springer C; Zhang C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4324-7. PubMed ID: 20615692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoids in the heart and vasculature: new insights for old hormones.
    Lother A; Moser M; Bode C; Feldman RD; Hein L
    Annu Rev Pharmacol Toxicol; 2015; 55():289-312. PubMed ID: 25251996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone synthase inhibitors in cardiovascular and renal diseases.
    Namsolleck P; Unger T
    Nephrol Dial Transplant; 2014 Feb; 29 Suppl 1():i62-i68. PubMed ID: 24493871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.
    Heim R; Lucas S; Grombein CM; Ries C; Schewe KE; Negri M; Müller-Vieira U; Birk B; Hartmann RW
    J Med Chem; 2008 Aug; 51(16):5064-74. PubMed ID: 18672861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
    Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Marchais-Oberwinkler S; Hartmann RW
    J Med Chem; 2006 Apr; 49(7):2222-31. PubMed ID: 16570918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?
    Ménard J; Pascoe L
    J Hypertens; 2006 Jun; 24(6):993-7. PubMed ID: 16685193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extra-adrenal mineralocorticoids and cardiovascular tissue.
    Slight SH; Joseph J; Ganjam VK; Weber KT
    J Mol Cell Cardiol; 1999 Jun; 31(6):1175-84. PubMed ID: 10371693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why are mineralocorticoid receptor antagonists cardioprotective?
    Chai W; Danser AH
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):153-62. PubMed ID: 17075718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW
    Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.
    Mulder P; Mellin V; Favre J; Vercauteren M; Remy-Jouet I; Monteil C; Richard V; Renet S; Henry JP; Jeng AY; Webb RL; Thuillez C
    Eur Heart J; 2008 Sep; 29(17):2171-9. PubMed ID: 18586661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease.
    Brem AS; Gong R
    Clin Sci (Lond); 2015 May; 128(9):527-35. PubMed ID: 25671776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.
    Brown NJ
    Nat Rev Nephrol; 2013 Aug; 9(8):459-69. PubMed ID: 23774812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.